Daclatasvir (Daklinza®)

Assessment Status NCPE Assessment Process Complete
Drug Daclatasvir
Brand Daklinza®
Indication In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4)
Assessment Process
Rapid review commissioned 05/08/2014
Rapid review completed 12/09/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 01/12/2014
NCPE assessment completed 29/05/2015
NCPE assessment outcome Reimbursement recommended for certain subgroups